{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T02:43:08Z","timestamp":1790476988648,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001827","name":"Universiteit van Amsterdam","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001827","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Samenwerkende Gezondheidsfondsen","award":["LSHM18055-SGF"],"award-info":[{"award-number":["LSHM18055-SGF"]}]},{"name":"Samenwerkende Gezondheidsfondsen","award":["LSHM18055-SGF"],"award-info":[{"award-number":["LSHM18055-SGF"]}]},{"name":"Samenwerkende Gezondheidsfondsen","award":["LSHM18055-SGF"],"award-info":[{"award-number":["LSHM18055-SGF"]}]},{"name":"Samenwerkende Gezondheidsfondsen","award":["LSHM18055-SGF"],"award-info":[{"award-number":["LSHM18055-SGF"]}]},{"name":"Samenwerkende Gezondheidsfondsen","award":["LSHM18055-SGF"],"award-info":[{"award-number":["LSHM18055-SGF"]}]},{"name":"Samenwerkende Gezondheidsfondsen","award":["LSHM18055-SGF"],"award-info":[{"award-number":["LSHM18055-SGF"]}]},{"name":"Samenwerkende Gezondheidsfondsen","award":["LSHM18055-SGF"],"award-info":[{"award-number":["LSHM18055-SGF"]}]},{"name":"Samenwerkende Gezondheidsfondsen","award":["LSHM18055-SGF"],"award-info":[{"award-number":["LSHM18055-SGF"]}]},{"name":"Samenwerkende Gezondheidsfondsen","award":["LSHM18055-SGF"],"award-info":[{"award-number":["LSHM18055-SGF"]}]},{"name":"Samenwerkende Gezondheidsfondsen","award":["LSHM18055-SGF"],"award-info":[{"award-number":["LSHM18055-SGF"]}]},{"name":"Samenwerkende Gezondheidsfondsen","award":["LSHM18055-SGF"],"award-info":[{"award-number":["LSHM18055-SGF"]}]},{"name":"Samenwerkende Gezondheidsfondsen","award":["LSHM18055-SGF"],"award-info":[{"award-number":["LSHM18055-SGF"]}]},{"DOI":"10.13039\/100007211","name":"Vasculitis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007211","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009425","name":"Landsteiner Foundation for Blood Transfusion Research","doi-asserted-by":"publisher","award":["Grant1626"],"award-info":[{"award-number":["Grant1626"]}],"id":[{"id":"10.13039\/100009425","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-99226-y","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T04:17:02Z","timestamp":1745813822000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Elevated Fab glycosylation of autoantibodies maintained during B cell depletion therapy"],"prefix":"10.1038","volume":"15","author":[{"given":"Anika M.","family":"Valk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Koers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ninotska I. L.","family":"Derksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Hogenboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zo\u00e9","family":"van Kempen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joep","family":"Killestein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Rutgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Heeringa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Horv\u00e1th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taco W.","family":"Kuijpers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Marieke","family":"van Ham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja ten","family":"Brinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"van der Woude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9 E. M.","family":"Toes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaas A.","family":"Bos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo","family":"Rispens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The T2B consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Eftimov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casper F. M.","family":"Franssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaap W.","family":"Groothoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnon","family":"Kater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"de Leeuw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liesbeth E. M.","family":"Oosten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"van Paassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uli H.","family":"Scherer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten J.","family":"Titulaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Verschuuren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niek","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine M. I.","family":"Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Hendrik","family":"Veelken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"van Baarsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Eldering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile A. C. M.","family":"van Els","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudi W.","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maartje G.","family":"Huijbers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Huizinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reina E.","family":"Mebius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelle","family":"de Wit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan G. M. C.","family":"Damoiseaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayel","family":"Abdulahad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabel M.","family":"Ruiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"van der Weele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karoline","family":"Kielbassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariateresa","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorit","family":"Verhoeven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyaysi","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam","family":"van der Burg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther M.","family":"Vletter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maaike","family":"Braham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Busch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Bonasia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Raveling-Eelsing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Verstegen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casper","family":"Marsman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocco","family":"Sciarillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Pollastro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Elias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koos","family":"van Dam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent M.","family":"Paardekooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9e","family":"Ysermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odilia B. J.","family":"Corneth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Buisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"van Binnendijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline A.","family":"van Schouwenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marvyn","family":"Koning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luuk","family":"Wieske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Y.","family":"Kummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelie","family":"Bos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"key":"99226_CR1","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41581-023-00720-1","volume":"19","author":"DS Pisetsky","year":"2023","unstructured":"Pisetsky, D. S. Pathogenesis of autoimmune disease. Nat. Rev. Nephrol. 19, 509\u2013524 (2023).","journal-title":"Nat. Rev. Nephrol."},{"key":"99226_CR2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S0161-5890(00)00038-9","volume":"37","author":"D Dunn-Walters","year":"2000","unstructured":"Dunn-Walters, D., Boursier, L. & Spencer, J. Effect of somatic hypermutation on potential N-glycosylation sites in human immunoglobulin heavy chain variable regions. Mol. Immunol. 37, 107\u2013113 (2000).","journal-title":"Mol. Immunol."},{"key":"99226_CR3","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.4049\/jimmunol.1502136","volume":"196","author":"FS van de Bovenkamp","year":"2016","unstructured":"van de Bovenkamp, F. S., Hafkenscheid, L., Rispens, T. & Rombouts, Y. The Emerging Importance of IgG Fab Glycosylation in Immunity. J. Immunol. 196, 1435\u20131441 (2016).","journal-title":"J. Immunol."},{"key":"99226_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212052","author":"RD Vergroesen","year":"2017","unstructured":"Vergroesen, R. D. et al. B-cell receptor sequencing of anti-citrullinated protein antibody (ACPA) IgG-expressing B cells indicates a selective advantage for the introduction of N -glycosylation sites during somatic hypermutation. Ann. Rheum. Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212052 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"99226_CR5","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/j.jaci.2022.10.035","volume":"151","author":"J Koers","year":"2023","unstructured":"Koers, J., Sciarrillo, R., Derksen, N. I. L. & Vletter, E. M. Differences in IgG autoantibody Fab glycosylation across autoimmune diseases. J. Allergy Clin. Immunol. 151, 1646\u20131654 (2023).","journal-title":"J. Allergy Clin. Immunol."},{"key":"99226_CR6","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1002\/art.40920","volume":"71","author":"L Hafkenscheid","year":"2019","unstructured":"Hafkenscheid, L. et al. N -Linked Glycans in the Variable Domain of IgG Anti-Citrullinated Protein Antibodies Predict the Development of Rheumatoid Arthritis. Arthr. Rheumatol. 71, 1626\u20131633 (2019).","journal-title":"Arthr. Rheumatol."},{"key":"99226_CR7","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1136\/annrheumdis-2014-206598","volume":"75","author":"Y Rombouts","year":"2016","unstructured":"Rombouts, Y. et al. Extensive glycosylation of ACPA-IgG variable domains modulates binding to citrullinated antigens in rheumatoid arthritis. Ann. Rheum. Dis. 75, 578\u2013585 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"99226_CR8","doi-asserted-by":"publisher","first-page":"158","DOI":"10.4049\/jimmunol.2200438","volume":"210","author":"M Volkov","year":"2023","unstructured":"Volkov, M. et al. IgG Fab Glycans Hinder FcRn-Mediated Placental Transport. J. Immunol. 210, 158\u2013167 (2023).","journal-title":"J. Immunol."},{"key":"99226_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/sciadv.abm1759","volume":"8","author":"T Kissel","year":"2022","unstructured":"Kissel, T. et al. Surface Ig variable domain glycosylation affects autoantigen binding and acts as threshold for human autoreactive B cell activation. Sci. Adv. 8, 1\u201322 (2022).","journal-title":"Sci. Adv."},{"key":"99226_CR10","doi-asserted-by":"publisher","first-page":"102804","DOI":"10.1016\/j.autrev.2021.102804","volume":"20","author":"X Zhou","year":"2021","unstructured":"Zhou, X. et al. Antibody glycosylation in autoimmune diseases. Autoimmun. Rev. 20, 102804 (2021).","journal-title":"Autoimmun. Rev."},{"key":"99226_CR11","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","volume":"20","author":"DSW Lee","year":"2021","unstructured":"Lee, D. S. W., Rojas, O. L. & Gommerman, J. L. B cell depletion therapies in autoimmune disease: Advances and mechanistic insights. Nat. Rev. Drug Discov. 20, 179\u2013199 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"99226_CR12","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","volume":"83","author":"ME Reff","year":"1994","unstructured":"Reff, M. E. et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83, 435\u2013445 (1994).","journal-title":"Blood"},{"key":"99226_CR13","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/art.21617","volume":"54","author":"MJ Leandro","year":"2006","unstructured":"Leandro, M. J., Cambridge, G., Ehrenstein, M. R. & Edwards, J. C. W. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arth. Rheum. 54, 613\u2013620 (2006).","journal-title":"Arth. Rheum."},{"key":"99226_CR14","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1002\/art.11181","volume":"48","author":"G Cambridge","year":"2003","unstructured":"Cambridge, G. et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthr. Rheum. 48, 2146\u20132154 (2003).","journal-title":"Arthr. Rheum."},{"key":"99226_CR15","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1093\/rheumatology\/ker417","volume":"51","author":"I De La Torre","year":"2012","unstructured":"De La Torre, I. et al. Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: Relationship with B-cell kinetics. Rheumatology 51, 833\u2013840 (2012).","journal-title":"Rheumatology"},{"key":"99226_CR16","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1093\/rheumatology\/kel393","volume":"46","author":"C Popa","year":"2006","unstructured":"Popa, C., Leandro, M. J., Cambridge, G. & Edwards, J. C. W. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology 46, 626\u2013630 (2006).","journal-title":"Rheumatology"},{"key":"99226_CR17","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1002\/art.40032","volume":"69","author":"FB Cortazar","year":"2017","unstructured":"Cortazar, F. B. et al. Effect of Continuous B Cell Depletion With Rituximab on Pathogenic Autoantibodies and Total IgG Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthr. Rheumatol. 69, 1045\u20131053 (2017).","journal-title":"Arthr. Rheumatol."},{"key":"99226_CR18","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1002\/art.24637","volume":"60","author":"RB Jones","year":"2009","unstructured":"Jones, R. B. et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthr. Rheum. 60, 2156\u20132168 (2009).","journal-title":"Arthr. Rheum."},{"key":"99226_CR19","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1136\/ard.2007.079095","volume":"67","author":"T Jonsdottir","year":"2007","unstructured":"Jonsdottir, T. et al. Treatment of refractory SLE with rituximab plus cyclophosphamide: Clinical effects, serological changes, and predictors of response. Ann. Rheum. Dis. 67, 330\u2013334 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"99226_CR20","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.clim.2006.08.016","volume":"122","author":"T Vallerskog","year":"2007","unstructured":"Vallerskog, T. et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin. Immunol. 122, 62\u201374 (2007).","journal-title":"Clin. Immunol."},{"key":"99226_CR21","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1182\/blood-2005-08-3518","volume":"107","author":"CM Bennett","year":"2006","unstructured":"Bennett, C. M. Prospective phase 1\/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood 107, 2639\u20132642 (2006).","journal-title":"Blood"},{"key":"99226_CR22","doi-asserted-by":"publisher","first-page":"e37626","DOI":"10.1371\/journal.pone.0037626","volume":"7","author":"N Venhoff","year":"2012","unstructured":"Venhoff, N. et al. Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides. PLoS ONE 7, e37626 (2012).","journal-title":"PLoS ONE"},{"key":"99226_CR23","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1002\/art.22025","volume":"54","author":"SB Cohen","year":"2006","unstructured":"Cohen, S. B. et al. Rituximab for rheumatoid arthritis refractory to anti\u2013tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthr. Rheum. 54, 2793\u20132806 (2006).","journal-title":"Arthr. Rheum."},{"key":"99226_CR24","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1002\/art.21260","volume":"52","author":"J Pijpe","year":"2005","unstructured":"Pijpe, J. et al. Rituximab treatment in patients with primary Sj\u00f6gren\u2019s syndrome: An open-label phase II study. Arthr. Rheum. 52, 2740\u20132750 (2005).","journal-title":"Arthr. Rheum."},{"key":"99226_CR25","doi-asserted-by":"publisher","DOI":"10.1177\/17562864221092092","author":"T Moser","year":"2022","unstructured":"Moser, T. et al. Long-term immunological consequences of anti-CD20 therapies on humoral responses to COVID-19 vaccines in multiple sclerosis: An observational study. Ther. Adv. Neurol. Disord. https:\/\/doi.org\/10.1177\/17562864221092092 (2022).","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"99226_CR26","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1136\/ard.2009.126441","volume":"69","author":"TG Kormelink","year":"2010","unstructured":"Kormelink, T. G. et al. Decrease in immunoglobulin free light chains in patients with rheumatoid arthritis upon rituximab (anti-CD20) treatment correlates with decrease in disease activity. Ann. Rheum. Dis. 69, 2137\u20132144 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"99226_CR27","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1136\/annrheumdis-2012-201956","volume":"72","author":"RF van Vollenhoven","year":"2013","unstructured":"van Vollenhoven, R. F. et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann. Rheum. Dis. 72, 1496\u20131502 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"99226_CR28","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser, S. L. et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N. Engl. J. Med. 376, 221\u2013234 (2017).","journal-title":"N. Engl. J. Med."},{"key":"99226_CR29","doi-asserted-by":"publisher","first-page":"102466","DOI":"10.1016\/j.autrev.2020.102466","volume":"19","author":"K Kridin","year":"2020","unstructured":"Kridin, K. & Ahmed, A. R. Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia. Autoimmun. Rev. 19, 102466 (2020).","journal-title":"Autoimmun. Rev."},{"key":"99226_CR30","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/1471-2474-15-178","volume":"15","author":"H Marco","year":"2014","unstructured":"Marco, H. et al. The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease. BMC Musculoskelet Disord. 15, 178 (2014).","journal-title":"BMC Musculoskelet Disord."},{"key":"99226_CR31","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1002\/art.23059","volume":"56","author":"E Keystone","year":"2007","unstructured":"Keystone, E. et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open-label extension analysis. Arthr. Rheum. 56, 3896\u20133908 (2007).","journal-title":"Arthr. Rheum."},{"key":"99226_CR32","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/acr.22993","volume":"69","author":"V Reddy","year":"2017","unstructured":"Reddy, V., Martinez, L., Isenberg, D. A., Leandro, M. J. & Cambridge, G. Pragmatic Treatment of Patients With Systemic Lupus Erythematosus With Rituximab: Long-Term Effects on Serum Immunoglobulins. Arthr. Care Res. (Hoboken) 69, 857\u2013866 (2017).","journal-title":"Arthr. Care Res. (Hoboken)"},{"key":"99226_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-59651-7","author":"DE Schmidt","year":"2020","unstructured":"Schmidt, D. E., De Haan, N., Sonneveld, M. E. & Porceli, L. IgG-Fc glycosylation before and after rituximab treatment in immune thrombocytopenia. Sci. Rep. https:\/\/doi.org\/10.1038\/s41598-020-59651-7 (2020).","journal-title":"Sci. Rep."},{"key":"99226_CR34","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.3390\/biomedicines10081774","volume":"10","author":"G Font","year":"2022","unstructured":"Font, G. et al. IgG N-glycosylation from Patients with Pemphigus Treated with Rituximab. Biomedicines 10, 1774 (2022).","journal-title":"Biomedicines"},{"key":"99226_CR35","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41582-021-00498-5","volume":"17","author":"MT Cencioni","year":"2021","unstructured":"Cencioni, M. T., Mattoscio, M., Magliozzi, R., Bar-Or, A. & Muraro, P. A. B cells in multiple sclerosis - from targeted depletion to immune reconstitution therapies. Nat. Rev. Neurol. 17, 399\u2013414 (2021).","journal-title":"Nat. Rev. Neurol."},{"key":"99226_CR36","doi-asserted-by":"publisher","first-page":"e21246","DOI":"10.1371\/journal.pone.0021246","volume":"6","author":"T Guhr","year":"2011","unstructured":"Guhr, T. et al. Enrichment of Sialylated IgG by Lectin Fractionation Does Not Enhance the Efficacy of Immunoglobulin G in a Murine Model of Immune Thrombocytopenia. PLoS ONE 6, e21246 (2011).","journal-title":"PLoS ONE"},{"key":"99226_CR37","doi-asserted-by":"publisher","first-page":"e37243","DOI":"10.1371\/journal.pone.0037243","volume":"7","author":"F K\u00e4sermann","year":"2012","unstructured":"K\u00e4sermann, F. et al. Analysis and Functional Consequences of Increased Fab-Sialylation of Intravenous Immunoglobulin (IVIG) after Lectin Fractionation. PLoS ONE 7, e37243 (2012).","journal-title":"PLoS ONE"},{"key":"99226_CR38","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.1002\/pmic.200800931","volume":"9","author":"J Stadlmann","year":"2009","unstructured":"Stadlmann, J. et al. A close look at human IgG sialylation and subclass distribution after lectin fractionation. Proteomics 9, 4143\u20134153 (2009).","journal-title":"Proteomics"},{"key":"99226_CR39","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1111\/jgh.14512","volume":"34","author":"EL Culver","year":"2019","unstructured":"Culver, E. L. et al. Unique patterns of glycosylation in immunoglobulin subclass G4-related disease and primary sclerosing cholangitis. J. Gastroenterol. Hepatol. 34, 1878\u20131886 (2019).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"99226_CR40","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1073\/pnas.1711720115","volume":"115","author":"FS van de Bovenkamp","year":"2018","unstructured":"van de Bovenkamp, F. S. et al. Adaptive antibody diversification through N-linked glycosylation of the immunoglobulin variable region. Proc. Natl. Acad. Sci. U S A 115, 1901\u20131906 (2018).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"99226_CR41","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ebiom.2017.01.033","volume":"17","author":"MJ Kemna","year":"2017","unstructured":"Kemna, M. J. et al. Galactosylation and Sialylation Levels of IgG Predict Relapse in Patients With PR3-ANCA Associated Vasculitis. EBioMedicine 17, 108\u2013118 (2017).","journal-title":"EBioMedicine"},{"key":"99226_CR42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ebiom.2022.104408","volume":"87","author":"J Van Coillie","year":"2023","unstructured":"Van Coillie, J. et al. The BNT162b2 mRNA SARS-CoV-2 vaccine induces transient afucosylated IgG1 in naive but not in antigen-experienced vaccinees. EBioMedicine 87, 1\u201319 (2023).","journal-title":"EBioMedicine"},{"key":"99226_CR43","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaut.2014.11.009","volume":"57","author":"DM Roberts","year":"2015","unstructured":"Roberts, D. M. et al. Rituximab-associated hypogammaglobulinemia: Incidence, predictors and outcomes in patients with multi-system autoimmune disease. J. Autoimmun. 57, 60\u201365 (2015).","journal-title":"J. Autoimmun."},{"key":"99226_CR44","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s12185-010-0528-6","volume":"91","author":"E Irie","year":"2010","unstructured":"Irie, E. et al. Severe hypogammaglobulinemia persisting for 6 years after treatment with rituximab combined chemotherapy due to arrest of B lymphocyte differentiation together with alteration of T lymphocyte homeostasis. Int. J. Hematol. 91, 501\u2013508 (2010).","journal-title":"Int. J. Hematol."},{"key":"99226_CR45","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1080\/07357900701809068","volume":"26","author":"AR Walker","year":"2008","unstructured":"Walker, A. R. et al. Profound hypogammaglobulinemia 7 years after treatment for indolent lymphoma. Cancer Invest. 26, 431\u2013433 (2008).","journal-title":"Cancer Invest."},{"key":"99226_CR46","doi-asserted-by":"publisher","first-page":"3949","DOI":"10.1002\/art.23127","volume":"56","author":"KN Verpoort","year":"2007","unstructured":"Verpoort, K. N. et al. Fine specificity of the anti-citrullinated protein antibody response is influenced by the shared epitope alleles. Arthr. Rheum. 56, 3949\u20133952 (2007).","journal-title":"Arthr. Rheum."},{"key":"99226_CR47","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/978-1-4939-8949-2_12","volume":"1901","author":"J Vanderlocht","year":"2019","unstructured":"Vanderlocht, J., van Beers, J. J. B. C., Limburg, P. C., Damoiseaux, J. & Roozendaal, C. Antigen-specific detection of autoantibodies against myeloperoxidase (MPO) and proteinase 3 (PR3). Methods Mol. Biol. 1901, 153\u2013176 (2019).","journal-title":"Methods Mol. Biol."},{"key":"99226_CR48","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/0896-8411(91)90163-7","volume":"4","author":"P Gueirard","year":"1991","unstructured":"Gueirard, P. et al. Anti-myeloperoxidase antibodies: Immunological characteristics and clinical associations. J. Autoimmun. 4, 517\u2013527 (1991).","journal-title":"J. Autoimmun."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-99226-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-99226-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-99226-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T05:02:09Z","timestamp":1745816529000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-99226-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["99226"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-99226-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,28]]},"assertion":[{"value":"27 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JK received research grants for multicentre investigator-initiated trials DOT-MS (NCT04260711, ZonMW), Supernext (NCT04225312, Treatmeds) and BLOOMS (NCT05296161, ZonMW and Treatmeds); received consulting fees from F Hoffmann-La Roche, Biogen, Teva, Merck, Novartis, and Sanofi\/Genzyme (all payments to institution); reports speaker relationships with F Hoffmann-La Roche, Biogen, Immunic, Teva, Merck, Novartis, and Sanofi\/Genzyme (all payments to institution); and is on the adjudication committee of MS clinical trials of Immunic (payments to institution only). All other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14770"}}